Literature DB >> 22425425

A comparison of propofol and amobarbital for use in the Wada test.

James A Magee1, Niall P Pender, Sharon Abrahams, John Thornton, Norman Delanty, Gillian M Fortune.   

Abstract

129 Wada procedures were reviewed to examine the suitability of propofol (n=54) as a replacement to amobarbital (n=75) for use as an anaesthetic in the Wada test. Suitability was considered with respect to length of hemiplegia induced, the frequency of side effects and patient memory scores. Data was retrospectively collected from records of patients who had undergone the Wada procedure between 2004 and 2009 in Beaumont Hospital, Dublin. No significant differences were found between the two drugs on any of the measures. The results suggest that propofol represents a suitable alternative to amobarbital for use in the Wada procedure.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425425     DOI: 10.1016/j.seizure.2012.02.001

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  4 in total

1.  Quantitative EEG is an objective, sensitive, and reliable indicator of transient anesthetic effects during Wada tests.

Authors:  Bin Tu; Nadege J Assassi; Carl W Bazil; Marla J Hamberger; Lawrence J Hirsch
Journal:  J Clin Neurophysiol       Date:  2015-04       Impact factor: 2.177

Review 2.  The malignant social network: cell-cell adhesion and communication in cancer stem cells.

Authors:  James S Hale; Meizhang Li; Justin D Lathia
Journal:  Cell Adh Migr       Date:  2012-07-01       Impact factor: 3.405

3.  Tolerability of propofol in Wada testing.

Authors:  Faisal A Alsallom; Shobhit Sinha; Fahmi M Alsenani; Fawziah A Bamogaddam; Saeed H Wahass; Aurora B Canillo; Khurram A Siddiqui
Journal:  Neurosciences (Riyadh)       Date:  2014-07       Impact factor: 0.906

4.  Experience of adverse events with cerebral propofol testing in patients with drug resistant epilepsy.

Authors:  Marta Szantroch; Aleksandra Bala; Andrzej Rysz; Jarosław Żyłkowski; Andrzej Marchel
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.